Naomi J Winick Selected Research

pegaspargase (Oncaspar)

10/2021	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
10/2020	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
10/2020	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
10/2018	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
1/2018	Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
1/2016	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
7/2015	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
7/2013	Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naomi J Winick Research Topics

Disease

43	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 11/2002
8	Neoplasms (Cancer) 08/2017 - 11/2002
7	Leukemia 01/2021 - 06/2011
6	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 10/2020 - 07/2015
5	Infections 01/2018 - 08/2008
4	Hypersensitivity (Allergy) 01/2018 - 07/2013
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 02/2015
3	Pancreatitis 01/2018 - 07/2013
3	Residual Neoplasm 01/2018 - 04/2012
2	Philadelphia Chromosome 01/2018 - 09/2014
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2011 - 11/2002
1	Central Nervous System Diseases (CNS Diseases) 10/2020
1	Cytopenia 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018
1	Cardiotoxicity 04/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2017
1	Hematologic Neoplasms (Hematological Malignancy) 12/2016
1	Osteonecrosis (Kienbock's Disease) 10/2016
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2016
1	Lymphoma (Lymphomas) 08/2014
1	Hearing Loss (Hearing Impairment) 11/2013
1	Ototoxicity 11/2013
1	Sensorineural Hearing Loss 11/2013
1	Febrile Neutropenia 11/2013
1	Thrombosis (Thrombus) 07/2013
1	Hemorrhage 07/2013
1	Hyperglycemia 07/2013
1	Fever (Fevers) 09/2008
1	Brain Neoplasms (Brain Tumor) 07/2007
1	Neuroblastoma 01/2004
1	Medulloblastoma 01/2004
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2002

Drug/Important Bio-Agent (IBA)

8	pegaspargase (Oncaspar)FDA Link 10/2021 - 07/2013
8	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 11/2002
6	Asparaginase (Elspar)FDA Link 10/2020 - 07/2013
4	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 02/2015
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 10/2016
3	nelarabine (506U78)FDA Link 10/2020 - 07/2015
2	lestaurtinibIBA 05/2021 - 01/2021
2	Leucovorin (Folinic Acid)FDA Link 10/2020 - 10/2018
2	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 02/2015
2	Transcription Factors (Transcription Factor)IBA 08/2017 - 09/2014
2	Biological ProductsIBA 01/2016 - 02/2007
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2004 - 01/2004
1	ElementsIBA 12/2019
1	methylervineIBA 10/2018
1	Clofarabine (Clolar)FDA Link 01/2018
1	prednylidene (Pred)IBA 01/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	GlucocorticoidsIBA 01/2018
1	Prednisone (Sone)FDA LinkGeneric 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 04/2017
1	AnthracyclinesIBA 04/2017
1	MicroRNAs (MicroRNA)IBA 04/2017
1	purineIBA 01/2016
1	Carboxypeptidases A (Carboxypeptidase A)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 07/2015
1	calaspargase pegolIBA 12/2014
1	Phosphotransferases (Kinase)IBA 09/2014
1	Tyrosine Kinase InhibitorsIBA 09/2014
1	AntibodiesIBA 08/2014
1	HLA Antigens (Human Leukocyte Antigens)IBA 08/2014
1	Pharmaceutical PreparationsIBA 08/2014
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2014
1	EpitopesIBA 08/2014
1	HLA-DRB1*07 antigenIBA 08/2014
1	EnzymesIBA 08/2014
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 11/2013
1	AminoglycosidesIBA 11/2013
1	Amikacin (A.M.K)FDA LinkGeneric 11/2013
1	PlatinumIBA 11/2013
1	Messenger RNA (mRNA)IBA 04/2012
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2012
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 07/2011
1	CyclinsIBA 06/2011
1	Adenosine Monophosphate (AMP)IBA 06/2011
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 06/2011
1	Carrier Proteins (Binding Protein)IBA 06/2011
1	trioctyl phosphine oxide (TOPO)IBA 06/2011
1	Tirapazamine (SR 4233)IBA 04/2004
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2004
1	Cytochrome P-450 CYP3AIBA 11/2002

Therapy/Procedure

24	Therapeutics 12/2021 - 11/2002
16	Drug Therapy (Chemotherapy) 01/2022 - 01/2004
2	Radiotherapy 12/2021 - 07/2007
2	Cranial Irradiation 10/2018 - 01/2018
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Intravenous Infusions 01/2018
1	Intramuscular Injections 01/2018
1	Ambulatory Care (Outpatient Care) 02/2015
1	Remission Induction 11/2012
1	Aftercare (After-Treatment) 06/2011
1	Salvage Therapy 07/2007
1	Duration of Therapy 01/2004